ESMO Insights | Professor Hope S. Rugo: KEYNOTE-B49 Shows PFS Benefit with Immunotherapy Plus Chemotherapy in HR+/HER2− Advanced Breast Cancer
At the 2026 ESMO Congress, Professor Hope S. Rugo of City of Hope Comprehensive Cancer Center, California, USA, presented the interim analysis (IA) and final analysis (FA) results of the KEYNOTE-B49 study. The findings showed that pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) in patients with PD-L1 CPS ≥1, HR-positive/HER2-negative advanced breast cancer (ABC). The PFS benefit was more pronounced in the subgroup with PD-L1 CPS ≥10. In addition, the immunotherapy combination more than tripled the 24-month PFS rate, with an overall manageable safety profile. These findings suggest that some patients with endocrine-resistant and more aggressive disease may benefit from immunotherapy. Oncology Frontier interviewed Professor Hope S. Rugo at the ESMO Congress to discuss the key findings from KEYNOTE-B49, the clinical benefits observed in specific subgroups, and the role of PD-L1 testing in guiding clinical practice.
Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care
Breast cancer is the most commonly diagnosed malignancy among women worldwide. With continued advances in systemic treatment and surgical techniques, patient survival has improved significantly, making postoperative quality of life and the restoration of physical and psychological well-being increasingly important components of comprehensive breast cancer care. Breast reconstruction is not only a concentrated expression of surgical expertise but also an important means of helping patients return to normal life, making it an integral part of breast cancer prevention and treatment.
Xinghai Forum | Professor Man Li: Advancing Precision and Collaborative Innovation in Comprehensive Cancer Care
To further promote standardized and precision-based cancer treatment, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was jointly organized by the Beijing Cancer Prevention and Control Society and the Beijing Breast Cancer Prevention and Control Society, co-organized by the Oncology Branch of the Dalian Medical Association, and hosted by the Second Affiliated Hospital of Dalian Medical University. The conference was held in Dalian from November 6 to 8, 2026, in a hybrid online and in-person format. Under the theme "Focus on Precision, Collaborate for Innovation," the meeting brought together leading experts from across China in liver cancer, lung cancer, gastrointestinal tumors, breast cancer, lymphoma, gynecologic oncology, immunotherapy, and other fields. Participants delivered presentations on the latest clinical applications and research advances in cancer care. Oncology Frontier invited Professor Man Li of the Second Affiliated Hospital of Dalian Medical University, Chair of the Conference, to introduce the program and highlights of the meeting and share her perspectives on patient education and the research development of young physicians.
Xinghai Forum | Professor Qiang Zhang: Building on Standards, Empowering Through Collaboration, Advancing Precision—The “Liaoning Experience” in Breast Specialty Development and Emerging Trends in Breast Surgery
From November 6 to 8, 2026, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was successfully held. After seven years of development, the Xinghai Forum has grown into an academic platform that brings together multiple disciplines and showcases cutting-edge advances in oncology. During the conference, Professor Qiang Zhang of the Cancer Hospital Affiliated with Dalian University of Technology shared the “Liaoning experience” in breast specialty development. Professor Zhang emphasized the importance of establishing standards and technical expertise as the foundation, giving equal priority to clinical practice and research, and advancing MDT and full-cycle patient management. In developing specialized disease centers, priorities should include establishing unified standards, strengthening talent development, building shared research platforms, and standardizing long-term data follow-up. As breast surgery moves toward greater precision and functional preservation, surgeons must be equipped with both a comprehensive treatment philosophy and a diverse range of surgical skills. This article summarizes the key points from the interview for our readers.
2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies
Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute in Spain, to share his latest research findings and academic insights into the mechanisms underlying the acquisition of stem-like plasticity in B-cell lymphomas and emerging targeted therapeutic strategies. The key points are presented below for our readers.
Xinghai Forum | Professor Haibo Wang: Patient-Centered, Multidisciplinary Integration—The “Qingdao Experience” in Breast Specialty Development
From November 6 to 8, 2026, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was held with great fanfare. After seven years of development, the Xinghai Forum has grown into an academic platform that brings together multiple disciplines and showcases cutting-edge advances in oncology. During the conference, Professor Haibo Wang of the Affiliated Hospital of Qingdao University shared the “Qingdao experience” in breast specialty development. Professor Wang emphasized the importance of remaining patient-centered and integrating multidisciplinary resources to provide patients with one-stop, precision multidisciplinary team (MDT) diagnosis and treatment services. Breast cancer treatment is not a matter of “fighting alone”; rather, it requires both continuous advancement in surgical techniques and the development of comprehensive systemic medical treatment capabilities to jointly improve the quality of care throughout the breast cancer journey. Professor Wang stressed that the development of specialized disease centers must avoid a department-centered approach and instead maintain a patient-centered focus and multidisciplinary balance. This article summarizes the key points from the interview for our readers.
Roundtable Discussion | Professors Yap Yoon Sim, Man Li, and Janice Tsang: Breaking Down Regional Barriers and Exploring New Paradigms in Breast Cancer Care and Full-Cycle Management Across Asia-Pacific
Innovative breast cancer therapies and high-quality clinical evidence are advancing at an unprecedented pace. However, significant differences persist across regions in biomarker testing standards, drug approval and access timelines, and real-world follow-up systems. These disparities create delays and gaps in translating cutting-edge evidence into clinical practice. At the recently held 2026 Academic Conference on Advances in Breast Cancer Diagnosis and Treatment in Northeast China, Oncology Frontier invited Professor Yap Yoon Sim of the National Cancer Centre Singapore, Professor Man Li of the Second Affiliated Hospital of Dalian Medical University, and Professor Janice Tsang of the Li Ka Shing Faculty of Medicine, The University of Hong Kong, to discuss how the Asia-Pacific region can move beyond academic exchange toward generating shared clinical evidence, and how to bridge the gaps between clinical trials and full-cycle patient management in real-world practice. Drawing on the healthcare systems and clinical experience of their respective regions, the three experts offered valuable perspectives on developing a shared framework for comprehensive breast cancer care across the Asia-Pacific region.
ESMO Voices from China | Professor Qingqing Cai: Rocbrutinib Plus R-CHOP as First-Line Treatment for Non-GCB DLBCL—Deep Responses and a Favorable Long-Term Safety Profile with No Atrial Fibrillation or Major Bleeding
Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) is characterized by substantial molecular heterogeneity. Compared with the GCB subtype, it generally responds less favorably to conventional immunochemotherapy and is associated with poorer outcomes, making it a challenging subtype in clinical practice. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Qingqing Cai's team from Sun Yat-sen University Cancer Center presented data from a multicenter Phase Ib study (1457O) evaluating the safety and preliminary efficacy of rocbrutinib, a novel fourth-generation Bruton tyrosine kinase (BTK) inhibitor, in combination with R-CHOP as first-line treatment for B-cell lymphoma. The study demonstrated an objective response rate (ORR) of 100% and a complete response (CR) rate of 86.7% among patients with newly diagnosed non-GCB DLBCL, with no cases of atrial fibrillation or severe bleeding observed. In this article, we invited Professor Qingqing Cai to provide an in-depth interpretation of the translational value and future research directions of this regimen, covering its pharmacological mechanisms, minimal residual disease (MRD)-guided strategies, and the future clinical development landscape.
2026 CTIC Congress | Professor Mohamad Mohty: Ending Four Decades of Stagnation in cGVHD—From Decoding Pathological Mechanisms to a New Era of Cell Therapy
Qiantang Forum, Shaping the Future Through Innovation. From November 6 to 8, 2026, the 2026 Cellular Therapy and Immunotherapy Conference (CTIC 2026) was grandly held in Hangzhou. Taking a global perspective, the congress brought together leading experts and scholars from China and abroad to explore cutting-edge developments in cellular therapy, gene therapy, AI-enabled hematology, and translational research, addressing clinical challenges and charting a path toward high-quality development in the field. During the congress, Oncology Frontier – Hematology Frontier invited Professor Mohamad Mohty of Sorbonne University, France, who also served as the congress chair, to share his latest research findings and academic insights into mechanistic breakthroughs in chronic graft-versus-host disease (cGVHD) over the past decade, the immunological balance between GVHD and GVL, and the future role of cell therapy. The key points are presented below.








